MedTrace Logo

Amyotrophic Lateral Sclerosis: a New Paradigm

NCT03073239 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2018-07-23

No results posted yet for this study

Summary

Amyotrophic Lateral Sclerosis (ALS) is a degenerative neuromuscular disease, progressing inexorably to respiratory failure, the by involvement of respiratory muscles, the commitment with most impact on the prognosis of ALS.

According to current knowledge, the clinical presentation of the disease is characterized by spinal or bulbar involvement, the latter being associated with a worse prognosis.

There are multiple factors described in the aetiology of ALS, as the successive damage the motor neuron, which can happen in high-impact athletes, or exposure to heavy metals. Genetic mutations are also described, being associated to a higher prevalence of ALS.

Data from retrospective studies with ALS populations reveal a prevalence of 4-8 cases per 100,000 persons. Research carried out in Trás-os-Montes e Alto Douro region (Northeast of Portugal) shows a high prevalence of ALS, with near 10 cases per 100,000 persons, with a recent increase in the bulbar involvement. The reasons for the high prevalence of ALS in this region are unknown.

Conditions

Interventions

GENETIC

ALS patients genetic characterization

Genetic findings in ALS patients

OTHER

ALS patients epidemiological caracterization

Epidemiological characterization in ALS patients

Sponsors & Collaborators

  • Conde, Bebiana, M.D.

    lead INDIV

Principal Investigators

  • Bebiana Conde, MD · Centro Hospitalar Tras-os-Montes e Alto Douro

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2018-03-31
Completion
2018-06-30

Countries

  • Portugal

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03073239 on ClinicalTrials.gov